RE:Share Price Excelleration
ha yes ......Memories...readit......After going through the approval process, Provenge was given full approval by the FDA on April 29, 2010. April 30, 2010 ..............$54.96 When Provenge was approved in 2010, analysts projected the treatment could generate $4.3 billion in annual sales by 2020. Now, they predict $378 million, based on two estimates compiled by Bloomberg August 4, 2011 ..........Dendreon's stock value fell 66% on after abandoning its forecast for its debut drug Provenge. November 2014, Dendreon filed for Chapter 11 bankruptcy protection and shortly afterwards announced that it had reached agreements on the terms of a financial restructuring with certain bond holders.[4] On February 20, 2015, Valeant Pharmaceuticals received approval to purchase all Dendreon assets.